Drug Target Review – Issue #3 2017
Posted: 6 September 2017 | Drug Target Review | No comments yet
Included in this issue: The importance of industry partnerships; Calcilytics as potential novel therapeutic treatments to halt Alzheimer’s disease; Accelerating neuroscience research with flow cytometry…
- Foreword: The importance of industry partnerships
Chris Watkins, Director of Innovation, Medical Research Council - In-Depth Focus: Assays
- Research Area: Alzheimer’s Disease – Calcilytics as potential novel therapeutic treatments to halt Alzheimer’s disease
Anna Chiarini, Ubaldo Armato and Ilaria Dal Prà, University of Verona - In-Depth Focus: Imaging
- Stem Cells: EUTCD-Grade lines – an innovative approach to creating and supplying clinical hESC lines
Glyn Stacey, UK Stem Cell Bank - Flow Cytometry: accelerating neuroscience research
Pushpanathan Muthuirulan, National Institute of Health - In-Depth Focus: NGS
The digital version of issue #3 2017 is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Assays, Drug Discovery, Flow Cytometry, Mass Spectrometry, Next Generation Sequencing (NGS), Screening, X-ray crystallography
Related conditions
Alzheimer’s disease
Related organisations
Eurofins Discovery, PerkinElmer, Thermo Fisher Scientific